Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

SAB4300609

Sigma-Aldrich

Anti-FLT4 antibody produced in rabbit

affinity isolated antibody

Synonyme(s) :

Anti-FLT41 antibody produced in rabbit, Anti-LMPH1A antibody produced in rabbit, Anti-PCL antibody produced in rabbit, Anti-VEGFR3 antibody produced in rabbit, Anti-fms-related tyrosine kinase 4 antibody produced in rabbit

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Numéro MDL:
MFCD03097363
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

rabbit

Niveau de qualité

100

Conjugué

unconjugated

Forme d'anticorps

affinity isolated antibody

Type de produit anticorps

primary antibodies

Clone

polyclonal

Forme

buffered aqueous solution

Poids mol.

~160 kDa

Espèces réactives

human

Concentration

1 mg/mL

Technique(s)

western blot: 1:500-1:1000

Isotype

IgG

Séquence immunogène

(L-A-S-E-E)

Numéro d'accès NCBI

NP_002011.2

Numéro d'accès UniProt

P35916

Conditions d'expédition

wet ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

human ... FLT4(2324)

Description générale

Fms related tyrosine kinase 4 (FLT4) is also known as vascular endothelial growth factor receptor 3 (VEGFR3). It is expressed in the blood and lymphatic endothelial cells during early development. The gene encoding FLT4 is localized on human chromosome 5q35.3.

Immunogène

Peptide sequence around aa. 1279-1283 (L-A-S-E-E), according to the protein FLT4.

Application

Anti-FLT4 antibody produced in rabbit has been used in immunohistochemistry.

Actions biochimiques/physiologiques

Fms related tyrosine kinase 4 (FLT4) has a role in lymphangiogenesis and angiogenesis. It acts as an activator in signaling pathways. Mutations in the gene encoding FLT4 have been linked to Milroy disease.

Caractéristiques et avantages

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Description de la cible

Receptor for VEGFC. Has a tyrosine-protein kinase activity.

Forme physique

Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions
Guo, Tianhua, et al
Genes Chromosomes Cancer (2011)
A novel FLT4 Gene mutation and MR lymphangiography in a Chinese family with Milroy disease
Liu, N., et al.
Lymphology, 93-6 (2015)
Molecular controls of lymphatic VEGFR3 signaling
Deng, Yong et al.
Atherosclerosis: Treatment and Prevention (2014)
Two anti-angiogenic TKI-PET tracers, [11C]axitinib and [11C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents
Paul S, et al.
Nuclear Medicine and Biology null
Silvia D'Alessio et al.
The Journal of clinical investigation, 124(9), 3863-3878 (2014-08-12)
Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBDs) of unknown etiology that are associated with an aberrant mucosal immune response. Neoangiogenesis and vascular injury are observed in IBD along with increased lymphangiogenesis. While the pathogenic
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique